(NYSE: CRL) Charles River Laboratories International's forecast annual revenue growth rate of 2.38% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.53%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.78%.
Charles River Laboratories International's revenue in 2026 is $4,015,382,000.On average, 18 Wall Street analysts forecast CRL's revenue for 2026 to be $198,043,439,400, with the lowest CRL revenue forecast at $184,850,389,000, and the highest CRL revenue forecast at $211,679,540,000. On average, 18 Wall Street analysts forecast CRL's revenue for 2027 to be $203,950,775,400, with the lowest CRL revenue forecast at $187,016,412,200, and the highest CRL revenue forecast at $222,214,289,200.
In 2028, CRL is forecast to generate $212,713,323,800 in revenue, with the lowest revenue forecast at $192,923,748,200 and the highest revenue forecast at $233,782,822,200.